Effect of de novo donor-specific HLA alloantibodies on cardiac function and mortality after heart transplantation

Bing TU; Jie HUANG; Zhongkai LIAO; Zhe ZHENG; Yunhu SONG; Wei WANG; Shengshou HU.
Chinese Journal of Organ Transplantation ; (12): 257-261, 2017.
Artículo en Zh | WPRIM | ID: wpr-621386

Documentos relacionados

  1. Chronic intermittent intravenous immunoglobulin in heart transplant recipients with elevated donor-specific antibody levels.
  2. Impact of Transient and Persistent Donor-Specific Antibodies in Lung Transplantation.
  3. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.
  4. Preemptive treatment of early donor-specific antibodies with IgA- and IgM-enriched intravenous human immunoglobulins in lung transplantation.
  5. Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant.
  6. Post-transplant de novo anti-HLA donor specific antibodies may contribute to poor graft function after haploidentical haematopoietic stem cell transplantation.
  7. Autoantibodies and Donor-specific Antibodies are Associated With Graft Dysfunction in Pediatric Liver Transplantation.
  8. Treatment of Antibody-Mediated Rejection After Kidney Transplantation: Immunological Effects, Clinical Response, and Histological Findings.
  9. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
  10. Anti-HLA sensitization after kidney allograft nephrectomy: changes one year post-surgery and beneficial effect of intravenous immunoglobulin.